177 related articles for article (PubMed ID: 20812364)
1. Sorafenib therapy in patients with hepatocellular carcinoma before liver transplantation.
Rowe IA
Hepatology; 2010 Sep; 52(3):1171-2. PubMed ID: 20812364
[No Abstract] [Full Text] [Related]
2. Hepatocellular carcinoma: sorafenib before liver transplantation?
Braillon A
Hepatology; 2010 Jun; 51(6):2232-3. PubMed ID: 20041410
[No Abstract] [Full Text] [Related]
3. Safe use of sorafenib in a patient undergoing salvage liver transplantation for recurrent hepatocellular carcinoma after hepatic resection.
Kim R; Menon N; Aucejo F
Med Oncol; 2011 Dec; 28(4):1044-7. PubMed ID: 20635167
[TBL] [Abstract][Full Text] [Related]
4. Hepatocellular carcinoma: the search for innovative adjuvant therapies.
Yen Y; Zhou W
Oncology (Williston Park); 2009 Dec; 23(14):1291, 1294. PubMed ID: 20120843
[No Abstract] [Full Text] [Related]
5. Sorafenib use in hepatocellular carcinoma in Japan: early experience and impact on clinical practice.
Zhu AX
Clin Drug Investig; 2012 Aug; 32 Suppl 2():1-2. PubMed ID: 22873622
[No Abstract] [Full Text] [Related]
6. Sorafenib-induced severe acute hepatitis in a stable liver transplant recipient.
Herden U; Fischer L; Schäfer H; Nashan B; von Baehr V; Sterneck M
Transplantation; 2010 Jul; 90(1):98-9. PubMed ID: 20606568
[No Abstract] [Full Text] [Related]
7. Sorafenib in hepatocellular carcinoma.
Josephs DH; Ross PJ
Br J Hosp Med (Lond); 2010 Aug; 71(8):451-6. PubMed ID: 20852487
[TBL] [Abstract][Full Text] [Related]
8. Fatal hemobilia in advanced hepatocellular carcinoma invading biliary tract after treatment with sorafenib and biliary stenting.
Verset G; Maréchal R; Bali MA; Devière J; Van Laethem JL
Ann Oncol; 2010 Jun; 21(6):1381-1382. PubMed ID: 20332137
[No Abstract] [Full Text] [Related]
9. Potential impact of sorafenib on the survival benefit of liver transplantation for hepatocellular carcinoma.
Vitale A; Lombardi G; Ramirez Morales R; Cillo U
Dig Liver Dis; 2012 May; 44(5):361-2. PubMed ID: 22424640
[No Abstract] [Full Text] [Related]
10. Sorafenib for liver cancer: the horizon broadens.
Johnson P; Billingham L
Lancet Oncol; 2009 Jan; 10(1):4-5. PubMed ID: 19111238
[No Abstract] [Full Text] [Related]
11. Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma.
Ahn HK; Lee S; Sun JM; Lee J; Park SH; Park JO; Park YS; Kang WK; Lim HY
Invest New Drugs; 2012 Aug; 30(4):1768-72. PubMed ID: 21720741
[No Abstract] [Full Text] [Related]
12. Liver transplantation in a patient treated by sorafenib for hepatocellular carcinoma.
Borentain P; Gregoire E; Hardwigsen J; Garcia S; Durieux O; Le Treut YP; Gérolami R
Clin Res Hepatol Gastroenterol; 2011 Mar; 35(3):234-6. PubMed ID: 21345761
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib for HCC: a pragmatic perspective.
Razumilava N; Gores GJ
Oncology (Williston Park); 2011 Mar; 25(3):300, 302. PubMed ID: 21548475
[No Abstract] [Full Text] [Related]
14. Sorafenib, a systemic therapy for hepatocellular carcinoma.
Méndez-Sánchez N; Vásquez-Fernández F; Zamora-Valdés D; Uribe M
Ann Hepatol; 2008; 7(1):46-51. PubMed ID: 18376365
[TBL] [Abstract][Full Text] [Related]
15. Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies.
Matsuda Y; Ichida T; Fukumoto M
Med Mol Morphol; 2011 Sep; 44(3):117-24. PubMed ID: 21922382
[TBL] [Abstract][Full Text] [Related]
16. Doxorubicin plus sorafenib in treatment of advanced hepatocellular carcinoma.
Pazo Cid RA; Lao J; Lanzuela M
JAMA; 2011 Feb; 305(8):781; author reply 781. PubMed ID: 21343576
[No Abstract] [Full Text] [Related]
17. Candidacy for sorafenib in HCC patients: is there a slippery slope beyond a SHARP edge?
Burak KW
Oncology (Williston Park); 2011 Mar; 25(3):296, 298, 300. PubMed ID: 21548474
[No Abstract] [Full Text] [Related]
18. Commentary: Sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy.
Zhu AX; Clark JW
Oncologist; 2009 Jan; 14(1):67-9. PubMed ID: 19147690
[No Abstract] [Full Text] [Related]
19. Health-related quality of life and sorafenib.
Spinzi G; Terreni N
Hepatology; 2010 Oct; 52(4):1523. PubMed ID: 20672386
[No Abstract] [Full Text] [Related]
20. Commentary: Sorafenib -- the end of a long journey in search of systemic therapy for hepatocellular carcinoma, or the beginning?
Abou-Alfa GK
Oncologist; 2009 Jan; 14(1):92-4. PubMed ID: 19144679
[No Abstract] [Full Text] [Related]
[Next] [New Search]
